MCID: ALL009
MIFTS: 50

Allergic Conjunctivitis

Categories: Immune diseases, Neuronal diseases

Aliases & Classifications for Allergic Conjunctivitis

MalaCards integrated aliases for Allergic Conjunctivitis:

Name: Allergic Conjunctivitis 12 15 17 71
Conjunctivitis, Allergic 43
Conjunctivitis Allergic 54

Classifications:



External Ids:

Disease Ontology 12 DOID:11204
MeSH 43 D003233
NCIt 49 C34506
SNOMED-CT 67 473460002
UMLS 71 C0009766

Summaries for Allergic Conjunctivitis

Disease Ontology : 12 A chronic conjunctivitis that is an inflammation of the conjunctiva involing red, itchy, and watery eyes a resulting from an exposure to an allergen or an irritant.

MalaCards based summary : Allergic Conjunctivitis, also known as conjunctivitis, allergic, is related to giant papillary conjunctivitis and pollen allergy. An important gene associated with Allergic Conjunctivitis is HRH1 (Histamine Receptor H1), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Pheniramine and Ketorolac have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and skin, and related phenotypes are hematopoietic system and immune system

Wikipedia : 74 Allergic conjunctivitis (AC) is inflammation of the conjunctiva (the membrane covering the white part of... more...

Related Diseases for Allergic Conjunctivitis

Diseases related to Allergic Conjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 543)
# Related Disease Score Top Affiliating Genes
1 giant papillary conjunctivitis 32.8 RNASE3 IL4 CXCL8 CCL11
2 pollen allergy 32.2 RNASE3 IL5 IL13 IGHE ICAM1 FOXP3
3 papillary conjunctivitis 31.2 IL4 CXCL8 CCL11
4 vernal keratoconjunctivitis 31.0 RNASE3 IL5 IL4 IL13 IGHE CCL11
5 allergic rhinitis 30.9 RNASE3 IL5 IL4 IL13 IL10 IGHE
6 vernal conjunctivitis 30.8 RNASE3 IL4 IGHE IFNG
7 cytokine deficiency 30.8 IL5 IL13
8 atopic keratoconjunctivitis 30.7 RNASE3 IL5 IL4 IL2 IGHE IFNG
9 keratopathy 30.4 TNF IL4 ICAM1 CXCL8
10 dacryoadenitis 30.4 IL4 IL13 IL10
11 haemophilus influenzae 30.3 TNF CXCL8
12 trachoma 30.0 TNF IL4 IL10 FOXP3
13 thymoma 29.9 TNF IL4 IL2 FOXP3
14 pertussis 29.9 TNF IL10 CXCL8 CCL11
15 secondary progressive multiple sclerosis 29.9 IL4 IL10 IFNG
16 scleritis 29.9 TNF IL5 IL4 IFNG
17 autoimmune lymphoproliferative syndrome 29.8 TNF IL2 IL10 FOXP3
18 ige responsiveness, atopic 29.8 RNASE3 IL5 IL4 IL13 IL10 IGHE
19 chlamydia 29.8 TNF IL5 IL4 IL10 IFNG CXCL8
20 latex allergy 29.8 TNF RNASE3 IL5 IL4 IL13 IGHE
21 herpes zoster 29.8 TNF IL2 IL10 IFNG
22 vogt-koyanagi-harada disease 29.7 TLR3 IL10 IFNG
23 keratoconjunctivitis 29.7 TNF RNASE3 IL5 IL4 IL2 IL13
24 myasthenia gravis 29.6 TNF IL4 IL2 IL10 IFNG
25 urticaria 29.5 TNF RNASE3 IL5 IL4 IL13 IL10
26 angioedema 29.4 IL5 IGHE HRH1
27 hypereosinophilic syndrome 29.4 RNASE3 IL5 IL4 IL2 IL13 IL10
28 eye disease 29.3 TNF IL5 IL4 IL2 IL13 IL10
29 chronic conjunctivitis 29.1 TNF RNASE3 IL5 IL4 IL33 IL13
30 allergic asthma 29.0 RNASE3 IL5 IL4 IL13 IL10 IGHE
31 uveitis 29.0 TNF IL4 IL2 IL10 IFNG ICAM1
32 bronchitis 29.0 TNF RNASE3 IL5 IL4 IL13 IL10
33 contact dermatitis 28.7 TNF IL5 IL4 IL33 IL2 IL10
34 autoimmune disease 28.7 TNF IL5 IL4 IL2 IL13 IL10
35 allergic contact dermatitis 28.7 TNF IL5 IL4 IL33 IL10 IFNG
36 rhinitis 28.5 TNF RNASE3 IL5 IL4 IL33 IL13
37 dermatitis 28.4 TNF SOCS3 IL5 IL4 IL2 IL13
38 conjunctival disease 28.4 TNF TLR3 RNASE3 IL5 IL4 IL33
39 food allergy 28.1 TNF RNASE3 IL5 IL4 IL13 IL10
40 allergic hypersensitivity disease 27.9 TNF RNASE3 IL5 IL4 IL33 IL2
41 proteasome-associated autoinflammatory syndrome 1 27.8 TNF TLR3 RNASE3 IL5 IL4 IL13
42 conjunctivitis 26.6 TNF TLR3 SOCS5 SOCS3 RNASE3 PTGDR2
43 inflammatory bowel disease 25.9 TNF TLR3 SOCS3 IL5 IL4 IL33
44 dermatitis, atopic 25.7 TNF TLR3 SOCS3 RNASE3 PTGDR2 IL5
45 asthma 24.8 TNF TLR3 SOCS3 RNASE3 PTGDR2 IL5
46 blepharitis 11.6
47 1-chloro-2,4-dinitrobenzene allergic contact dermatitis 10.6 IL4 IL2
48 virus associated hemophagocytic syndrome 10.6 IL4 IL2
49 loeffler endocarditis 10.5 RNASE3 IL5
50 punctate inner choroidopathy 10.5 TNF IL10

Graphical network of the top 20 diseases related to Allergic Conjunctivitis:



Diseases related to Allergic Conjunctivitis

Symptoms & Phenotypes for Allergic Conjunctivitis

MGI Mouse Phenotypes related to Allergic Conjunctivitis:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.36 CCL11 FOXP3 HRH1 ICAM1 IFNG IL10
2 immune system MP:0005387 10.31 CCL11 FOXP3 HRH1 ICAM1 IFNG IL10
3 homeostasis/metabolism MP:0005376 10.28 FOXP3 HRH1 ICAM1 IFNG IL10 IL13
4 endocrine/exocrine gland MP:0005379 10.27 FOXP3 ICAM1 IFNG IL10 IL13 IL1RL1
5 growth/size/body region MP:0005378 10.26 FOXP3 HRH1 ICAM1 IFNG IL10 IL13
6 digestive/alimentary MP:0005381 10.25 FOXP3 ICAM1 IFNG IL10 IL13 IL2
7 integument MP:0010771 10.07 FOXP3 ICAM1 IFNG IL10 IL13 IL33
8 liver/biliary system MP:0005370 9.97 FOXP3 HRH1 IFNG IL10 IL2 IL4
9 neoplasm MP:0002006 9.8 ICAM1 IFNG IL10 IL2 IL5 TLR3
10 no phenotypic analysis MP:0003012 9.76 FOXP3 IFNG IL10 IL13 IL2 IL33
11 reproductive system MP:0005389 9.7 FOXP3 IFNG IL10 IL13 IL2 IL33
12 respiratory system MP:0005388 9.4 CCL11 FOXP3 IFNG IL10 IL13 IL2

Drugs & Therapeutics for Allergic Conjunctivitis

Drugs for Allergic Conjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 140)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pheniramine Approved Phase 4 86-21-5 4761
2
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
3
Alcaftadine Approved Phase 4 147084-10-4 19371515
4
Bepotastine Approved Phase 4 190786-44-8, 125602-71-3 2350
5
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
6
Ketotifen Approved Phase 4 34580-13-7, 34580-14-8 3827
7
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
8
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
9
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
10
Desloratadine Approved, Investigational Phase 4 100643-71-8 124087
11
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 9865442 444025
12
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
13
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
14
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
15 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
16
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
17
Dipivefrin Approved Phase 4 52365-63-6 3105
18
Montelukast Approved Phase 4 158966-92-8 5281040
19
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
20
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
21
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
22
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
23
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
24
Maleic acid Experimental, Investigational Phase 4 110-17-8, 110-16-7 444972
25
Tranilast Investigational Phase 4 53902-12-8 93543
26
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
27 Ketorolac Tromethamine Phase 4
28 Respiratory System Agents Phase 4
29 Dermatologic Agents Phase 4
30 Anti-Asthmatic Agents Phase 4
31 Lubricant Eye Drops Phase 4
32 Bronchodilator Agents Phase 4
33 Immunosuppressive Agents Phase 4
34 Calcineurin Inhibitors Phase 4
35 Gastrointestinal Agents Phase 4
36 Hormones Phase 4
37 Antineoplastic Agents, Hormonal Phase 4
38 Antiemetics Phase 4
39 Hormone Antagonists Phase 4
40 glucocorticoids Phase 4
41 Platelet Aggregation Inhibitors Phase 4
42 Calcium, Dietary Phase 4
43 calcium channel blockers Phase 4
44 Dextrans Phase 4
45 Anticoagulants Phase 4
46 Plasma Substitutes Phase 4
47 Blood Substitutes Phase 4
48 Cholinergic Agents Phase 4
49 Cholinergic Antagonists Phase 4
50 Methylprednisolone Acetate Phase 4

Interventional clinical trials:

(show top 50) (show all 224)
# Name Status NCT ID Phase Drugs
1 Comparison of Tolerability Between Two Allergy Drops Unknown status NCT01390961 Phase 4 alacaftadine and naphazoline HCl & pheniramine maleate
2 Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses Unknown status NCT01337557 Phase 4 Bepotastine
3 To Assess the Impact of Ocular Allergy Treatment on Patients Using an Opthalmic Agent (or no Treatment) Versus Alcaftadine(Lastacaft™) Unknown status NCT01808768 Phase 4 Alcaftadine
4 Topical Tacrolimus in Vernal Keratoconjunctivitis Unknown status NCT02456025 Phase 4 Topical tacrolimus
5 Topical Application of ACULAR a Randomized, Vehicle Controlled Clinical Trial: Efficiency in Inhibiting Proliferative Retinopathy of Prematurity Unknown status NCT00634972 Phase 4 ACULAR;REFRESH TEARS;placebo
6 A Comparison of Olopatadine Versus Fluticasone Nasal Spray in the Prevention of the Signs and Symptoms of Allergic Conjunctivitis Completed NCT00655109 Phase 4 Olopatadine;Fluticasone;Saline;Artificial tears
7 Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients Completed NCT01109485 Phase 4 Olopatadine hydrochloride ophthalmic solution 0.1%
8 Patient Perception Study for AL-4943A Completed NCT01294969 Phase 4 AL-4943A
9 Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis Completed NCT01159769 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)
10 Mast-Cell Stabilizing Effects of Olopatadine Completed NCT00389025 Phase 4 Olopatadine (generic name)
11 Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR) Completed NCT00818805 Phase 4 Olopatadine 0.1%;Tranilast 0.5%;Placebo (Olopatadine);Placebo (Tranilast)
12 A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Completed NCT01470118 Phase 4 alcaftadine 0.25% ophthalmic solution;olopatadine 0.2% ophthalmic solution;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
13 Safety and Efficacy Comparison Ketotifen Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis Completed NCT00133627 Phase 4 Ketotifen
14 Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Pre and Post Treatment With Olopatadine HCL Ophthalmic Solution, 0.2% Completed NCT01697969 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2%
15 A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy Completed NCT02308501 Phase 4 Lastacaft ®;Tears Naturale ®
16 A Single-Center, Masked, Randomized Study Comparing Two Marketed Ocular Anti-Allergy Medications in the Cat Room Model Completed NCT00534794 Phase 4 Elestat;Pataday
17 A Multi-Site, Open-Label Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis Completed NCT01272089 Phase 4 Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
18 Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Completed NCT01203540 Phase 4 NAABAK eyedrops;Saline eyedrops
19 A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis Completed NCT01732757 Phase 4 Alcaftadine 0.25%;Olopatadine 0.2%;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
20 The Effect of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer Completed NCT01346371 Phase 4 Refresh Tears 0.5% Lubricant Eye Drops;Bepreve 1.5% Ophthalmic Solution
21 A Double-blind, Placebo-controlled, Crossover, Single-center Study to Evaluate the Anti-allergic and Anti-inflammatory Effects of Multiple Doses of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms Completed NCT00311844 Phase 4 desloratadine
22 Effectiveness of Olopatadine HCl Ophthalmic Solution, 0.1% Compared to Epinastine HCl Ophthalmic Solution, 0.05% in the Treatment of Allergic Conjunctivitis to Japanese Cedar Pollen Completed NCT02251613 Phase 4 Olopatadine HCl ophthalmic solution, 0.1%;Epinastine HCl ophthalmic solution, 0.05%
23 A Single-Center, Randomized, Double-Masked, Placebo-Controlled Evaluation of the Efficacy of Flonase (Fluticasone Propionate Nasal Spray) Compared to Placebo Nasal Spray in the Allergen BioCube (ABC) Model Completed NCT01439815 Phase 4 Fluticasone Propionate Nasal Spray;Saline Nasal Spray
24 A Single-Center, Masked, Randomized Study Comparing Bepreve (Bepotastine Besilate) 1.5% - H1 Specific Antihistamine vs. Alrex (Loteprednol Etabonate) 0.2% - Corticosteroid in Subjects With Moderate to Severe Allergic Conjunctivitis Completed NCT01443442 Phase 4 bepotastine besilate, 1.5%;Loteprednol etabonate
25 A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5% Completed NCT01437982 Phase 4 Loteprednol Etabonate;Prednisolone Acetate 1% Oph Susp
26 A Randomized, Double-Masked, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of Maxidex® (0.1% Dexamethasone) Ophthalmic Suspension and Patanol® (0.1% Olopatadine Hydrochloride) Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in an Environmental Exposure Chamber (EEC) Model Completed NCT01119287 Phase 4 Dexamethasone 0.1% ophthalmic suspension;Olopatadine hydrochloride 0.1% ophthalmic solution
27 A Study to Assess Alcon's Ocular Image Quantification Using Conjunctival Allergan Provocation Testing (CAPT) and Natural Allergen Exposure in an Environmental Exposure Chamber (EEC) Completed NCT01282138 Phase 4 Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)
28 A Phase 4, Randomized, Double-Masked, Single Center, Placebo-Controlled Adaptive Clinical Trial, Using Prednisolone Sodium Phosphate Ophthalmic Solution, 1%, in Subjects With Allergic Conjunctivitis to Evaluate a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT01534195 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
29 Comparison of the Effect of Fluticasone Furoate Nasal Spray Versus Placebo on Allergic Mediators in the Tears of Subjects With Tree or Grass Pollen Allergy Completed NCT00891436 Phase 4 Fluticasone furoate nasal spray;Placebo nasal spray
30 Single Center, Randomized, Double-Masked Evaluation of the Efficacy of Prednisolone Acetate 1% Ophthalmic Suspension Compared to Prednisolone Acetate 0.12% Ophthalmic Suspension, Loteprednol Etabonate 0.2% Ophthalmic Suspension, and Placebo in a Modified CAC Model Completed NCT00689078 Phase 4 Prednisolone Acetate 1%;Prednisolone Acetate 0.12%;Loteprednol Etabonate 0.2%;Placebo
31 A Prospective, Randomized, Open, Multi-centre Study to Assess Safety of PURETHAL Grasses Given With a Rush Induction Schedule to Patients With Allergic Rhinoconjunctivitis Completed NCT01059266 Phase 4 PURETHAL Grasses, 20.000 AUM/ml
32 A Single-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of Prednisolone Sodium Phosphate Ophthalmic Solution, 1% Compared to Placebo in a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT01730872 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
33 Montelukast as a Controller of Atopic Syndrome Completed NCT00559546 Phase 4 montelukast
34 Investigating the Efficacy of Artificial Tear Supplements and Cold Compresses for the Treatment of Seasonal Allergic Conjunctivitis Completed NCT01569191 Phase 4 Anti-allergic Medication
35 Topical Cyclosporine in the Treatment of Vernal Keratoconjunctivitis in a Rwandan Eye Clinic; a Prospective Randomized Double-masked Clinical Trial Completed NCT01211327 Phase 4 Cyclosporine A;Dexamethasone
36 Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal Keratoconjunctivitis Completed NCT00357019 Phase 4 N-acetyl-aspartyl-glutamate (NAAXIA Sine)
37 Observational National Clinical Trial of Safety and Tolerance in Patients Suffering of an Allergic Grass Pollen Rhinitis and Treated by Grazax in Real Life Settings Completed NCT01433510 Phase 4 Grazax
38 A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis Completed NCT03464435 Phase 4 Tacrolimus
39 Bilastine and Montelukast in Patients With Seasonal Allergic Rhinoconjunctivitis and Asthma: Efficacy of Concomitant Administration - the SKY Study Completed NCT02761252 Phase 4 Bilastine 20mg;Montelukast 10mg;Placebo Bilastine 20mg;Placebo Montelukast 10mg
40 The Evaluation of the Effect of Bepreve, a Topical Ocular Antihistamine, on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing Completed NCT01128556 Phase 4 Bepreve;Refresh Tears
41 A Randomized Clinical Trial Comparing the Intraocular Pressure Changes With the Use of Loteprednol and Dexamethasone After Pterygium Surgery Completed NCT00781300 Phase 4 Loteprednol Etabonate 0.5%;Dexamethasone 0.1%
42 Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops: Prospective Double-Blind Randomized Study Completed NCT01850979 Phase 4 Tacrolimus;Olive Oil
43 Randomized Controlled Trial Comparing Olopatadine 0.1% Ophthalmic Solution With Hylo-Dual Ophthalmic Preparation in Children With Seasonal Allergic Conjunctivitis Recruiting NCT03186755 Phase 4 Hyaluronic acid 0.05% & Ectoine 2.0%;Olopatadine hydrochloride ophthalmic solution 0.1%
44 Alleviation of Cedar Pollen Induced Allergic Symptoms by Orally Taken Superfine Beta-1,3-Glucan - A Double-Blind Randomized Study Terminated NCT00276445 Phase 4 beta-1,3-glucan
45 Comparison of CL Wear Between Epinastine Hydrochloride and Olopatadine Hydrochloride Withdrawn NCT00489398 Phase 4 epinastine HCL and olopatadine HCL
46 A Phase 4 Study to Assess the Clinical Efficacy and Safety of Manuka Eye Drops for Treatment of Allergy Withdrawn NCT03862053 Phase 4 Manuka honey
47 A Multicenter, Double-Blind, Placebo-Controlled Study With a Modified Allergen Extract for Specific Immunotherapy in Patients With Seasonal Allergic Rhinitis/Rhinoconjunctivitis Unknown status NCT01012752 Phase 3
48 Use of Probiotic Bacteria in Prevention of Allergic Disease in Children 1999-2008 Unknown status NCT00298337 Phase 2, Phase 3 Mixture of probiotic bacteria and prebiotic oligosaccharide
49 A Randomised Double Blind Placebo-controlled, Long-term Phase III Study to Assess the Efficacy and Safety of Oralgen Grass Pollen in Patients With Grass Pollen Related Allergic Rhinoconjunctivitis Unknown status NCT00812799 Phase 3 Oralgen
50 AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis Completed NCT02082262 Phase 3 AGN-229666

Search NIH Clinical Center for Allergic Conjunctivitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Antazoline
Antazoline Hydrochloride
Antazoline Phosphate
Astemizole
azelastine
Azelastine hydrochloride
bepotastine
bepotastine besilate
carbinoxamine
Carbinoxamine maleate
Ketorolac Tromethamine
levocabastine
Levocabastine hydrochloride
Loteprednol
loteprednol etabonate
medrysone
Nedocromil
Nedocromil Sodium
olopatadine
Olopatadine hydrochloride
pemirolast
Pemirolast potassium
Pyrilamine
Pyrilamine Maleate
PYRILAMINE TANNATE
Triprolidine
Triprolidine Hydrochloride

Cochrane evidence based reviews: conjunctivitis, allergic

Genetic Tests for Allergic Conjunctivitis

Anatomical Context for Allergic Conjunctivitis

MalaCards organs/tissues related to Allergic Conjunctivitis:

40
Eye, Testes, Skin, T Cells, Lung, Thymus, Endothelial

Publications for Allergic Conjunctivitis

Articles related to Allergic Conjunctivitis:

(show top 50) (show all 1742)
# Title Authors PMID Year
1
Clinical evaluation of total IgE in tears of patients with allergic conjunctivitis disease using a novel application of the immunochromatography method. 61 54
19779297 2009
2
Is serum total IgE levels a good predictor of allergies in children? 54 61
19813686 2009
3
Relationship between myopia and allergen-specific serum IgE levels in patients with allergic conjunctivitis. 61 54
19788663 2009
4
Emedastine difumarate: a review of its potential ameliorating effect for tissue remodeling in allergic diseases. 61 54
19558341 2009
5
[Lacrimal assessment of lg E in cases with allergic conjunctivitis]. 54 61
20361659 2009
6
Serum allergen specific immunoglobulin E levels in patients with allergic conjunctivitis. 61 54
18850541 2008
7
The early efficacy of topical levocabastine in patients with allergic conjunctivitis. 61 54
17075271 2006
8
Allergens in Japanese patients with allergic conjunctivitis in autumn. 61 54
15389269 2005
9
Eotaxin-1 (CCL11) up-regulation in tears during seasonal allergic conjunctivitis. 54 61
15221302 2004
10
Correlations between allergen-specific IgE serum levels in patients with allergic conjunctivitis in spring. 54 61
15209463 2004
11
Tear and serum eosinophil cationic protein levels in seasonal allergic conjunctivitis. 61 54
14620169 2003
12
Human ocular mast cells. 54 61
12582326 2002
13
Ocular tolerability and safety of ketotifen fumarate ophthalmic solution. 61 54
12431041 2002
14
Respiratory syncytial virus may be a pathogen in allergic conjunctivitis. 61 54
11995809 2002
15
The relative contribution of mast cell subsets to conjunctival TH2-like cytokines. 61 54
11274077 2001
16
Genetics of allergic disease: evidence for organ-specific susceptibility genes. 61 54
11306967 2001
17
Dissociation of allergen-specific IgE and IgA responses in sera and tears of pollen-allergic patients: a study performed with purified recombinant pollen allergens. 54 61
10756233 2000
18
Tear and serum soluble leukocyte activation markers in conjunctival allergic diseases. 61 54
10682966 2000
19
Tear levels of interferon-gamma, interleukin (IL) -2, IL-4 and IL-5 in patients with vernal keratoconjunctivitis, atopic keratoconjunctivitis and allergic conjunctivitis. 61 54
10606937 2000
20
[Measurement of total IgE in tears : the adaptation of an immunoenzyme technique and the value of investigating locally produced IgE in the diagnosis of chronic conjunctivitis]. 61 54
10432371 1999
21
Expression of ICAM-1 on conjunctival epithelium and ECP in tears and serum from children with allergic conjunctivitis. 61 54
10400487 1999
22
Tear IgE concentrations in allergic conjunctivitis. 54 61
9683958 1998
23
Immunolocalization of cytokines to mast cells in normal and allergic conjunctiva. 61 54
9420138 1997
24
Characterization of cytokine mRNA transcripts in conjunctival cells in patients with allergic conjunctivitis. 61 54
9191598 1997
25
Sustained eosinophil cationic protein release into tears after a single high-dose conjunctival allergen challenge. 54 61
8911697 1996
26
Eosinophil cationic protein in tears in allergic conjunctivitis. 54 61
8759270 1996
27
A new murine model of allergic conjunctivitis and effectiveness of nedocromil sodium. 54 61
8626992 1996
28
Measurement of interleukin-4 and histamine in superficial cells of conjunctiva in patients with allergic conjunctivitis. 54 61
8670730 1996
29
Interleukin-4 and IgE in seasonal allergic conjunctivitis. 61 54
8887388 1996
30
Detection of allergen-specific IgE in tears of grass pollen-allergic patients with allergic rhinoconjunctivitis. 54 61
8789546 1996
31
Measurement of IL-4 in tears of patients with seasonal allergic conjunctivitis and vernal keratoconjunctivitis. 54 61
7586697 1995
32
[Importance of the lacrymal levels (total IgE, specific IgE and albumin) for the study of allergic conjunctivitis]. 54 61
8185822 1994
33
The origin of keratopathy in chronic allergic eye disease: a histopathological study. 61 54
8253220 1993
34
Asthma phenotypes and associated comorbidities in a large cohort of adolescents in Israel. 61
31017024 2020
35
A Case of Early Keratoconus Associated with Eye Rubbing in a Young Child. 61
32542504 2020
36
Leukotriene B4 receptors as therapeutic targets for ophthalmic diseases. 61
32535236 2020
37
Allergen-specific immunotherapy for patients with atopic dermatitis sensitized to animal dander. 61
32162849 2020
38
Selected cytokine expression in dogs with alergic conjunctivitis: Correlation with disease activity. 61
32114248 2020
39
Seasonality of allergic diseases: Real-world evidence from a nationwide population-based study. 61
32533645 2020
40
Characterization of Photodegradation Products of Bepotastine Besilate and In Silico Evaluation of Their Physicochemical, Absorption, Distribution, Metabolism, Excretion and Toxicity Properties. 61
32173321 2020
41
Efficacy of Alcaftadine 0.25% (AGN-229666) for Once-daily Prevention of Cedar-Pollen Allergic Conjunctivitis: A Phase 3 Randomized Study. 61
32501774 2020
42
Sympathetic Nerves Positively Regulate Eosinophil-Driven Allergic Conjunctivitis via α1-Adrenergic Receptor Signaling. 61
32194050 2020
43
The allergic eye: recommendations about pharmacotherapy and recent therapeutic agents. 61
32558665 2020
44
Ocular allergy test and biomarkers on the ocular surface: Clinical test for evaluating the ocular surface condition in allergic conjunctival diseases. 61
32563624 2020
45
Novel Polyvinyl Pyrrolidone-Loaded Olopatadine HCl-Laden Doughnut Contact Lens to Treat Allergic Conjunctivitis. 61
32007507 2020
46
In vitro-in vivo evaluation of tetrahydrozoline-loaded ocular in situ gels on rabbits for allergic conjunctivitis management. 61
32359095 2020
47
[Recommendations for performing specific inhalation challenge tests: Polish experience in relation to the European Respiratory Society guideliness]. 61
32401234 2020
48
[Are Fungal Spores Relevant Outdoor Allergens?] 61
32384555 2020
49
[An epidemiological survey on clinical features, self-management and cognitive level of elderly asthmatics in China]. 61
32392995 2020
50
Patient-Oriented Eczema Measure score: A Useful Tool for Web-Based Surveys in Patients with Atopic Dermatitis. 61
32449786 2020

Variations for Allergic Conjunctivitis

Expression for Allergic Conjunctivitis

Search GEO for disease gene expression data for Allergic Conjunctivitis.

Pathways for Allergic Conjunctivitis

Pathways related to Allergic Conjunctivitis according to GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.08 TNF TLR3 SOCS5 SOCS3 RNASE3 IL5
2
Show member pathways
13.77 TNF SOCS5 SOCS3 IL5 IL4 IL33
3
Show member pathways
13.64 TNF SOCS5 SOCS3 IL5 IL4 IL2
4
Show member pathways
13.47 TNF TLR3 IL5 IL4 IL2 IL13
5
Show member pathways
13.36 TNF IL5 IL4 IL2 IL13 IL10
6
Show member pathways
13.31 TNF SOCS5 SOCS3 IL5 IL4 IL33
7
Show member pathways
13.26 TNF TLR3 SOCS5 SOCS3 IL4 IL2
8
Show member pathways
13.12 TNF TLR3 SOCS3 IL2 IL10 IFNG
9
Show member pathways
12.94 TNF TLR3 SOCS3 IL33 IL2 IFNG
10 12.9 IL5 IL4 IL2 IL13 IFNG CXCL8
11
Show member pathways
12.89 TNF RNASE3 IL5 IL4 IL2 IL13
12
Show member pathways
12.81 TNF SOCS5 SOCS3 IL4 IL2
13
Show member pathways
12.76 TNF TLR3 IL33 IL1RL1 CXCL8
14
Show member pathways
12.73 TNF SOCS3 IL5 IL4 IL2 IL13
15
Show member pathways
12.71 TNF IL4 IL2 IL10 IGHE IFNG
16 12.69 TNF TLR3 SOCS3 IL4 IL2 IL10
17
Show member pathways
12.68 TNF IL5 IL4 IL2 IL10 IFNG
18
Show member pathways
12.64 TNF SOCS3 IL2 IL10 IFNG
19
Show member pathways
12.64 TNF IL5 IL4 IL13 IGHE
20
Show member pathways
12.59 SOCS5 SOCS3 IL5 IL4 IL2 IL13
21
Show member pathways
12.58 TNF IL4 IL2 IFNG ICAM1
22
Show member pathways
12.52 SOCS5 SOCS3 IL4 IGHE HRH1 CCL11
23
Show member pathways
12.48 TNF IL5 IL4 IL13 IFNG CXCL8
24
Show member pathways
12.41 TNF IL2 IL10 CXCL8 CCL11
25
Show member pathways
12.41 TNF IL4 IL2 IFNG ICAM1
26
Show member pathways
12.37 TNF SOCS3 IL5 IL4 IL2 IL13
27
Show member pathways
12.34 TNF TLR3 IFNG CXCL8
28
Show member pathways
12.31 TNF IL4 IL10 IFNG
29
Show member pathways
12.28 TNF IL4 IFNG CXCL8 CCL11
30
Show member pathways
12.25 TNF TLR3 IL33 IFNG
31 12.23 TNF IL13 IL10 CXCL8
32 12.16 TNF IL4 IL2 IFNG ICAM1 CXCL8
33 12.16 TNF PTGDR2 IL5 IL4 IL2 IL10
34
Show member pathways
12.1 TLR3 IL5 IL2 IL13
35 12.08 TNF IL2 IL10 CXCL8
36
Show member pathways
12.07 TNF TLR3 IL2 IL10 IFNG
37 12 TNF IL10 IFNG CXCL8
38 11.95 TNF IFNG ICAM1 CXCL8
39 11.95 IL5 IL4 IL2 IL13 IFNG ICAM1
40
Show member pathways
11.9 TNF IL5 IL4 IL2 IFNG FOXP3
41 11.84 TNF IL2 IL10 IFNG
42 11.84 TNF IL5 IL4 IL13 CXCL8 CCL11
43
Show member pathways
11.83 TNF IL2 IFNG ICAM1 CXCL8
44 11.79 TNF IL10 CXCL8
45 11.75 SOCS5 SOCS3 IL5 IL4 IL10 IGHE
46
Show member pathways
11.74 IL4 IL2 FOXP3
47 11.71 TNF IL10 IFNG ICAM1 CXCL8
48 11.71 TNF SOCS5 SOCS3 IL4 IL13 IL10
49
Show member pathways
11.69 TNF IL2 IFNG
50 11.69 TNF IL4 IL13 IL10 ICAM1 CXCL8

GO Terms for Allergic Conjunctivitis

Cellular components related to Allergic Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 TNF RNASE3 IL5 IL4 IL33 IL2
2 external side of plasma membrane GO:0009897 9.55 TNF IL1RL1 IL13 IGHE ICAM1
3 extracellular space GO:0005615 9.44 TNF TLR3 RNASE3 IL5 IL4 IL33

Biological processes related to Allergic Conjunctivitis according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.34 TLR3 PTGDR2 IL5 IL4 IL1RL1 IL10
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.25 TNF TLR3 IL4 IL33 IL2 IL10
3 positive regulation of gene expression GO:0010628 10.11 TNF TLR3 IL4 IL33 IL13 IFNG
4 defense response to bacterium GO:0042742 10.02 TNF TLR3 RNASE3 IL10 IGHE
5 inflammatory response GO:0006954 10.02 TNF TLR3 IL5 IL13 HRH1 CXCL8
6 cellular response to lipopolysaccharide GO:0071222 10 TNF IL10 ICAM1 CXCL8
7 response to virus GO:0009615 9.92 TNF TLR3 IFNG FOXP3 CCL11
8 cellular response to interleukin-1 GO:0071347 9.9 ICAM1 CXCL8 CCL11
9 regulation of growth GO:0040008 9.9 SOCS5 SOCS3 IFNG
10 positive regulation of interleukin-6 production GO:0032755 9.87 TNF TLR3 IL33
11 positive regulation of nitric oxide biosynthetic process GO:0045429 9.85 TNF IFNG ICAM1
12 extrinsic apoptotic signaling pathway GO:0097191 9.85 TNF TLR3 IL33 IFNG
13 positive regulation of inflammatory response GO:0050729 9.85 TNF TLR3 IL33 IL2 IL1RL1 IFNG
14 positive regulation of B cell proliferation GO:0030890 9.84 IL5 IL4 IL2 IL13
15 positive regulation of cytokine production GO:0001819 9.81 TNF TLR3 IL33
16 positive regulation of cytokine secretion GO:0050715 9.81 TNF IL10 IFNG
17 negative regulation of endothelial cell apoptotic process GO:2000352 9.81 IL4 IL13 IL10 ICAM1
18 positive regulation of JAK-STAT cascade GO:0046427 9.8 TNF IL5 IL10
19 JAK-STAT cascade GO:0007259 9.8 SOCS5 SOCS3 IFNG
20 negative regulation of interleukin-6 production GO:0032715 9.8 TNF SOCS5 IL10 FOXP3
21 regulation of regulatory T cell differentiation GO:0045589 9.77 IL2 IFNG FOXP3
22 positive regulation of chemokine secretion GO:0090197 9.77 TNF IL33 IL1RL1
23 positive regulation of immunoglobulin secretion GO:0051024 9.76 IL5 IL33 IL2
24 negative regulation of interferon-gamma production GO:0032689 9.76 IL33 IL1RL1 IL10 FOXP3
25 positive regulation of MHC class II biosynthetic process GO:0045348 9.75 IL4 IL10 IFNG
26 positive regulation of neuroinflammatory response GO:0150078 9.73 TNF IL33
27 positive regulation of podosome assembly GO:0071803 9.73 TNF IL5
28 positive regulation of interleukin-10 secretion GO:2001181 9.73 IL4 IL13
29 positive regulation of mast cell degranulation GO:0043306 9.73 IL4 IL13
30 negative regulation of T-helper 17 cell differentiation GO:2000320 9.73 IL4 IL2 FOXP3
31 positive regulation of macrophage activation GO:0043032 9.73 IL33 IL1RL1 IL13 IL10
32 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.73 TNF SOCS3 IL4 IL2 IL13 IFNG
33 immune response GO:0006955 9.73 TNF PTGDR2 IL5 IL4 IL2 IL1RL1
34 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.72 IL4 IL10
35 response to molecule of bacterial origin GO:0002237 9.72 IL10 CXCL8
36 negative regulation of amyloid-beta clearance GO:1900222 9.72 TNF IFNG
37 positive regulation of isotype switching to IgG isotypes GO:0048304 9.72 IL4 IL2
38 microglial cell activation GO:0001774 9.72 TNF TLR3 IL4 IL13 IFNG
39 branching involved in labyrinthine layer morphogenesis GO:0060670 9.71 SOCS3 IL10
40 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.71 TNF IFNG
41 positive regulation of interleukin-13 production GO:0032736 9.71 IL4 IL33
42 necroptotic signaling pathway GO:0097527 9.71 TNF TLR3
43 positive regulation of chemokine biosynthetic process GO:0045080 9.71 TNF TLR3 IL4 IFNG
44 endothelial cell apoptotic process GO:0072577 9.7 TNF IL10
45 positive regulation of interleukin-5 production GO:0032754 9.7 IL33 IL1RL1
46 negative regulation of inflammatory response GO:0050728 9.7 SOCS5 SOCS3 IL4 IL2 IL13 IL10
47 positive regulation of mononuclear cell migration GO:0071677 9.69 TNF IL4
48 negative regulation of lymphocyte proliferation GO:0050672 9.69 IL2 FOXP3
49 type 2 immune response GO:0042092 9.69 IL4 IL10
50 negative regulation of cytokine production involved in immune response GO:0002719 9.68 TNF IL10

Molecular functions related to Allergic Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.32 TNF IL5 IL4 IL33 IL2 IL13
2 growth factor activity GO:0008083 9.26 IL5 IL4 IL2 IL10

Sources for Allergic Conjunctivitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....